



Product Information

Product ID L1875

CAS No. 111358-88-4

Chemical Name (15S,16S,18R)-16-Hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1.15,18.02,6.07,27.08,13.019,26.020,25]octacosan

Synonym SP 924, A 154475.0, KT 5555, CEP-701

Formula C₂₆H₂₁N₃O₄

Formula Wt. 439.47

Melting Point


Purity ≥98%

Solubility DMSO 100mM
ethanol 25mM

Store Temp -20°C

Ship Temp Ambient

Description Lestaurtinib is an inhibitor of PRK1, JAK, and FLT3 that exhibits anticancer chemotherapeutic activity. Lestaurtinib inhibits growth and induces apoptosis in Hodgkin lymphoma cells and decreases tumor size in animal models of neuroblastoma.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
L1875	1 mg	\$126.00
L1875	5 mg	\$409.50
L1875	10 mg	\$735.00

References Chamberlain P, Delker S, Pagarigan B, et al. Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes. PLoS One. 2014 Aug 11;9(8):e103638. PMID: 25111382.

Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs. 2013 Jun;22(6):687-99. PMID: 23432430.

Diaz T, Navarro A, Ferrer G, et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One. 2011 Apr 20;6(4):e18856. PMID: 21533094.

Wiernik PH. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol. 2010 Jun;8(6):429-36, 444. PMID: 20733555.

Iyer R, Evans AE, Qi X, et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res. 2010 Mar 1;16(5):1478-85. PMID: 20179224.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.